Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Investors can obtain conference call details and view the live webcast via the company's Investors page, and a replay will be archived on the site for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RPRX gained 1.61%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RPRX was down 0.43% while peers were mixed: BNTX -0.22%, GMAB -5.51%, SMMT -1.27% versus INCY +0.63% and INSM +0.67%, with no peers in the momentum scanner and no same-day peer headlines.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Business update | Positive | +0.2% | JPM Healthcare Conference business update and 2025 guidance commentary. |
| Jan 11 | Pipeline funding deal | Positive | +0.2% | Up to $500M agreement with Teva to fund TEV-’408 development. |
| Jan 09 | Dividend increase | Positive | -0.2% | Announced higher first-quarter 2026 dividend of $0.235 per share. |
| Dec 29 | Royalty acquisition | Positive | -0.2% | Acquired remaining Evrysdi royalty interest for $240M plus milestones. |
| Dec 16 | Royalty acquisition | Positive | -0.4% | Acquired Nuvalent royalty interests in neladalkib and zidesamtinib. |
Recent positive strategic and dividend announcements have often seen flat to slightly negative next-day price reactions, suggesting a tendency for muted or fading responses to good news.
Over the last two months, Royalty Pharma has focused on capital deployment and portfolio growth, announcing $4.7 billion of 2025 transactions and expecting $3,200–$3,250 million in 2025 Portfolio Receipts with 14%–16% growth. It increased its quarterly dividend to $0.235 per share, a 6.8% rise, and expanded royalties in Evrysdi and Nuvalent assets. The upcoming Q4 and full-year 2025 earnings date fits into this cadence of updates, potentially providing formal detail on the previously discussed guidance and transaction activity.
Market Pulse Summary
This announcement sets the timeline for detailed disclosure of Royalty Pharma’s fourth quarter and full-year 2025 results on February 11, 2026. Investors can contextualize the coming report against prior guidance of $3,200–$3,250 million in 2025 Portfolio Receipts, recent $4.7 billion in transactions, and the higher quarterly dividend of $0.235 per share. Monitoring how reported figures track to these benchmarks and any updated outlook will be important once results are released.
AI-generated analysis. Not financial advice.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) release Q4 and full year 2025 results?
What time is the Royalty Pharma (RPRX) earnings call on February 11, 2026?
Where can investors find the Royalty Pharma (RPRX) webcast link and call details?
Will Royalty Pharma (RPRX) provide a replay of the February 11, 2026 earnings call?
Will Royalty Pharma (RPRX) report results before or after U.S. market open on February 11, 2026?
How can shareholders prepare for Royalty Pharma's (RPRX) February 11, 2026 call?
